Medtronic(US:MDT)2024-08-20 12:04Financial Performance - Medtronic's Q1 FY25 adjusted revenue reached $8.004 billion, reflecting a 5.3% organic growth[14, 46] - The adjusted diluted EPS was $1.23, showing a 7.5% increase in constant currency[14, 46] - The adjusted gross margin was 65.9%, up 30 bps year-over-year in constant currency[12, 46] - The operating margin was 24.4%, an increase of 60 bps year-over-year in constant currency[12, 46] - Operating cash flow was $1.0 billion, with a free cash flow of $0.5 billion[14] Segment Performance - Cardiovascular revenue reached $3.007 billion, with a 6.9% organic growth[14, 63] - Diabetes revenue was $647 million, demonstrating a 12.6% organic growth[14, 63] - Neuroscience revenue totaled $2.317 billion, reflecting a 5.3% organic growth[14, 63] - Medical Surgical revenue was $1.996 billion, with a 1.0% organic growth[14, 63] Guidance - Medtronic raised its FY25 organic revenue growth guidance to 4.5% to 5.0% from the previous 4.0% to 5.0%[12, 50] - The FY25 EPS guidance is $5.42 to $5.50[12, 51]